TNF and metabolic dysfunction-associated steatotic liver disease: However, despite having by now been acknowledged as one of the causal factors that markedly contributes to the progression of MASLD and especially that of MASH [14] as well as in light of promising pre-clinical studies employing anti-TNFα antibodies, there are still several gaps in the understanding how TNFα adds to the onset and progression of MASLD.